Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Atai Life Sciences N.V.
(NQ:
ATAI
)
1.980
UNCHANGED
Streaming Delayed Price
Updated: 10:50 AM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Atai Life Sciences N.V.
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
Psyched: Investment Banks Bullish On Atai Life Sciences, Wesana's $17M Purchase Of PsyTech, Creso Pharma Acquires Halucenex
July 19, 2021
A number of financial firms and investment banks
Via
Benzinga
Investment Banks Bullish On Psychedelics Co Atai Life Sciences: Cantor, Credit Suisse, Citigroup, Cowen, Aegis And Others Launch Coverage, Positive Ratings
July 16, 2021
This week, a number of financial firms and investment banks initiated coverage of Atai Life Sciences (NASDAQ:
Via
Benzinga
Palo Santo: New Venture Capital Group Raises $35M To Focus On Psychedelic Medicine
July 15, 2021
Palo Santo, a newly-created venture capital fund with an eye on psychedelic medicines, announced its official launch on Thursday.
Via
Benzinga
Post-COVID Investment Mega-Opportunity: Mental Health And Psychedelic Drug Stocks
July 15, 2021
After governments have obsessed for the past 18 months about COVID-19, they are now forced to confront a much larger pandemic: the Mental Health Pandemic. This enormous crisis is also a huge investing...
Via
Talk Markets
Exposures
COVID-19
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
July 11, 2021
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2021
July 14, 2021
Upgrades CL King upgraded the previous rating for Compass Minerals International Inc (NYSE:
Via
Benzinga
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
July 07, 2021
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021
July 13, 2021
Upgrades For Royal Dutch Shell PLC (NYSE:RDS), Bar...
Via
Benzinga
The 6 Leading Psychedelic Stocks In Drug R&D
July 07, 2021
Drug R&D in the emerging psychedelic drug industry continues to advance. Share prices continue to lag. Here's a comparison of the strengths and weaknesses of six of the leaders in psychedelic drug R&D...
Via
Talk Markets
Got $1,000? Consider This Freshly IPO'd Psychedelic Biotech
July 03, 2021
It's off to a running start.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2021
July 08, 2021
Upgrades For FB Financial Corp (NYSE:
Via
Benzinga
Atai IPO Day An Underwhelming Event
June 21, 2021
The IPO of atai Life Sciences was arguably the most-anticipated event in the emerging psychedelic drug industry. It failed to live up to expectations.
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
June 21, 2021
Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Opening Day: WalkMe Stock Price Falls Following $287M IPO
June 19, 2021
Backed by Insight Venture Partners, WalkMe fell as much as 7% in its trading debut earlier this week after a $287M initial public offering. According to filings, Insight will remain WalkMe's biggest...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public
June 18, 2021
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the...
Via
Benzinga
58 Biggest Movers From Friday
June 21, 2021
Gainers CAI International, Inc. (NYSE: CAI) shares surged 46.9% to close at $56.05 on Friday after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc....
Via
Benzinga
New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End
June 18, 2021
Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, after an upsized offering for the Atai IPO.
Via
Investor's Business Daily
Topics
Initial Public Offering
Exposures
Securities Market
Is ATAI Stock A Buy After The IPO?
June 16, 2021
ATAI Life Sciences will go public this week. And investors wanting to cash in on one of the hottest medicine and mental health trends need to pay attention to this stock.
Via
Talk Markets
IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings
June 14, 2021
This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Peter Thiel-Backed Psychedelic Firm Atai Sets Terms For US IPO, Sees $2.3B Valuation
June 11, 2021
Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, has announced terms for its initial public offer...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.